Can donor cells stop viruses after transplant?

NCT ID NCT04230356

Recruiting now Disease control Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is detected. The goal is to see if scheduled dosing reduces treatment failures and the need for harsh antiviral medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor-derived viral specific T-cells (VSTs)
What this could lead to: If successful, this approach could reduce severe viral infections after stem cell transplant and limit the need for toxic antiviral drugs.
What could go wrong: This is a Phase 2 trial with 180 participants, so results are still early. The treatment may not work for all viruses or could cause side effects like graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC STELL CELL TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC STELL CELL TRANSPLANT VIRAL INFECTION

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.